

Outpatient Treatment Options				
Treatment	Monoclonal Antibodies: Sotrovimab	Paxlovid (nirmatrelvir + ritonavir)	Molnupiravir	Fluvoxamine
Admin	Single IV infusion at the Baltimore Convention Center Field Hospital (BCCFH) COVID Task Force Infusion Center	300mg nirmatrelvir (two 150mg tablets) + 100mg ritonavir - three pills total PO BID for 5 days	800mg (four 200mg capsules) PO BID for 5 days	100mg PO BID for 10 days
Additional Info	Very limited supply. Prescribe only to the highest risk patients: Tier 1: Immunocompromised regardless of vaccine status OR UNvaccinated and ≥75yo (or ≥65yo + risk factors) Tier 2: Unvaccinated and ≥65yo (or younger + risk factors) Tier 3: Vaccinated and ≥75yo (or ≥65yo + risk factors) Tier 4: Vaccinated and ≥65yo (or younger + risk factors)			Supporting evidence is limited. Least likely to be beneficial. Widely available. Least risk.
Inclusion Criteria	Must meet all of the following: A. Symptom onset within 10 days B. No new O2 requirement nor an increase in baseline O2 due to COVID C. One or more of the following: 1. BMI >25 2. Chronic kidney disease 3. Diabetes 4. Immunosuppressive disease 5. On immunosuppressive treatment 6. ≥ 65 years of age 7. ≥ 55 years of age AND one or more: <ul style="list-style-type: none"> ○ Cardiovascular disease ○ Hypertension ○ Chronic lung disease 	Must meet all of the following: <ul style="list-style-type: none"> • Weigh 40+ kg • COVID+ • Symptom onset within 5 days • Have mild-moderate symptoms • Not hospitalized • At high risk for severe disease • GFR >30 • No severe hepatic impairment Medication Notes: - CYP3A inhibitor, medication interactions - Dose adjust for GFR 30-60 - Oral contraceptive pills may be rendered ineffective, back up recommended - Reduces risk of hospitalization and death by 89%	Must meet all of the following: <ul style="list-style-type: none"> • Weigh 40+ kg • COVID+ • Symptom onset within 5 days • Have mild-moderate symptoms • Not hospitalized • At high risk for severe disease • No other alternative treatments available • Not pregnant Medication Notes: - Reduces risk of hospitalization and death by 30%	<ul style="list-style-type: none"> • Symptom onset within 7 days • No other alternative treatments available Medication Notes: - Use in the third trimester of pregnancy may be associated with newborn pulmonary hypertension. Discuss risk/benefit with patients. - No reduction in hospitalization. Possible reduction in mortality. Higher quality studies needed.
How To Refer or Obtain Medication	Provider referral link Patient self-referral link (not active as of 12/28/21)	Prescribe oral medication to specific pharmacy with supply. Use Maryland-specific Website or National Website (filter by zipcode/state/city). Call the pharmacy after prescribing to ensure the patient will receive the medication and navigate delivery details like fee.		Standard prescription